Update shared on 06 Nov 2025
Fair value Decreased 1.34%Evonik Industries' analyst price target has been reduced slightly, with the updated consensus reflecting a minor decline of approximately EUR 0.25. Analysts cite ongoing cyclical and structural headwinds impacting earnings expectations.
Analyst Commentary
Recent analyst actions on Evonik Industries highlight a mix of optimism and caution, with several adjustments to price targets and ratings reflecting evolving sector conditions. The sentiment among the analyst community remains mixed, with some emphasizing long-term prospects while others exhibit increased caution due to external pressures.
Bullish Takeaways
- Bullish analysts maintain an Overweight rating. This indicates confidence in the company’s ability to execute despite near-term headwinds.
- Analysts adjusting price targets modestly downward believe the valuation remains compelling relative to industry peers. They see long-term fundamentals as intact.
- Continued support for the stock at higher price targets reflects conviction in Evonik’s resilience and growth potential once cyclical pressures moderate.
Bearish Takeaways
- Bearish analysts are downgrading their outlook, citing increasing downside risks to earnings estimates due to sustained structural and cyclical pressures.
- Lowered price targets suggest reduced confidence in near-term revenue and profit growth. This outlook is influenced by macroeconomic headwinds.
- Some analysts have shifted to a Hold stance, reflecting concerns about valuation levels and the potential impact of ongoing market challenges on future performance.
What's in the News
- Issued new earnings guidance for Q3 2025. Evonik expects revenue of approximately €3.4 billion, down from €3.8 billion in Q3 2024. (Key Developments)
- Announced a strategic collaboration with Ethris to develop and market a novel lipid nanoparticle (LNP) platform for nucleic acid delivery. This partnership aims for improved delivery of RNA-based therapies and vaccines. (Key Developments)
Valuation Changes
- Fair Value: Lowered modestly from €18.37 to €18.12. This reflects a slight decrease in the estimated intrinsic worth of Evonik Industries’ shares.
- Discount Rate: Reduced significantly from 6.31% to 5.08%. This indicates a lower required rate of return and potentially an improved risk profile.
- Revenue Growth: Increased from 0.24% to 1.57%, pointing to stronger expectations for top-line expansion.
- Net Profit Margin: Decreased slightly from 4.27% to 4.21%, suggesting a minor decline in expected profitability.
- Future P/E: Dropped from 15.77x to 14.99x, indicating a modest improvement in valuation multiples.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.